Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672486 | 1.00 | TLR9 (0.38) | TLR9TLR7TLR8PDCD1CD274 | |
| SCHEMBL3670078 | 0.83 | HRH3 (0.41) | TLR9TLR7TLR8PDCD1CD274 | |
| SCHEMBL3670077 | 0.83 | HRH3 (0.41) | TLR9TLR7TLR8PDCD1CD274 | |
| SCHEMBL3668166 | 0.83 | HRH3 (0.48) | TLR9TLR7TLR8PDCD1CD274 | |
| SCHEMBL3668162 | 0.83 | HRH3 (0.48) | TLR9TLR7TLR8PDCD1CD274 | |
| SCHEMBL3667209 | 0.81 | TLR8 (0.43) | TLR9TLR7TLR8HRH3MCHR1 | |
| SCHEMBL3667211 | 0.81 | TLR8 (0.43) | TLR9TLR7TLR8HRH3MCHR1 | |
| SCHEMBL3667320 | 0.81 | TLR8 (0.43) | TLR9TLR7TLR8HRH3MCHR1 | |
| SCHEMBL3667314 | 0.81 | TLR8 (0.43) | TLR9TLR7TLR8HRH3MCHR1 | |
| SCHEMBL3667205 | 0.79 | TLR9 (0.38) | TLR9TLR7TLR8PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-2238144-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | CYP11B2, CYP11B1, CYP4B1 | TLR9 4728/4885TLR7 3431/4885TLR8 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.